Introduction
Ketamine has been used clinically since the 1960s as a general anesthetic. 1 A decade after its approval by the US Food and Drug Administration, researchers showed that ketamine reduces the excitatory response to N-methyl-d-aspartic acid (NMDA) in central neurons, thus revealing its NMDA receptor antagonism properties 2 and advancing our understanding of the pharmacology of ketamine. Currently, clinicians use ketamine as a general anesthetic less frequently, given its emergence psychotomimetic effects and findings of neurotoxic effects shown in the developing brain of animals. 3 Conversely, over the past decade, researchers have explored the effect of subanesthetic doses of ketamine as an antidepressant 4 and as an analgesic. 5, 6 The use of subanesthetic ketamine as an analgesic is supported by evidence, from both animal and human studies, implicating activation of NMDA receptors in the pathobiology of nociceptive, inflammatory, and neuropathic pain and in central sensitization. 7 In addition, activation of NMDA receptors has also been shown in animals 8 and in human experimental studies 9 to play a role in settings where acute or chronic use of opioids is associated with tolerance or opioidinduced hyperalgesia. Therefore, based on these preclinical findings, ketamine has been examined clinically as an adjuvant to opioids for the treatment of acute and chronic pain and in settings of opioid-induced hyperalgesia. 6, 10 However, among clinical studies, there has been a great variability in ketamine doses and duration of administration. Additionally, the beneficial effects of ketamine have not been consistently reported, and some groups have been unable to show opioidsparing effects of ketamine in clinical settings associated with opioid-induced hyperalgesia. 11, 12 Similarly, in chronic pain, there are no definitive data supporting the use of ketamine for the treatment of chronic regional pain syndrome (CRPS) or other types of chronic pain. 13 Further, in critical reviews of available trials, researchers can only conclude that there might be a beneficial role for ketamine as an adjuvant to opioids to treat pain in the postoperative period, cancer pain, and chronic pain. 9, 12, 14, 15 Consequently, as outlined in clinical guidelines, the evidence to support the use of ketamine for the treatment of acute and chronic pain is at best moderate. 16, 17 However, despite lack of conclusive clinical evidence to support its use, clinicians from various disciplines in many countries continue to use ketamine as an adjuvant to opioids for acute and chronic pain management. [18] [19] [20] [21] Some argue that in the setting of limited effective pharmacologic options, one might be left with no alternative other than less studied strategies such as ketamine infusions. Our institution has used subanesthetic ketamine (defined as not >1 mg/kg/h) to treat acute and chronic pain in children, adolescents, and young adults since 2006. We have previously reported our experience using ketamine for the treatment of cancer pain, postoperative, and chronic pain. 5, 11 In this study, we sought to examine the use of subanesthetic ketamine in a large number of patients admitted to a tertiary pediatric hospital whose pain proved unresponsive to routine pharmacologic interventions. Specifically, we sought to determine the overall effect of ketamine on pain scores and opioid intake, to identify factors associated with larger or smaller effects and to examine the frequency with which ketamine was associated with clinically meaningful reductions in pain scores and opioid intake.
Methods

Data collection
The Children's National Health System Institutional Review Board approved this longitudinal cohort study and a waiver for written informed consent in 2014 (Pro00004569). Requirement for patient written consent to review their records was waived as this was a minimal risk study and the data collected were devoid of patient identifiers. Patients who had received subanesthetic doses of ketamine for pain management were eligible for inclusion in this study. We reviewed a list of all patients (obtained from the hospital pharmacy records) who were admitted between January 2006 and April 2014 and had received an order for continuous infusion of intravenous ketamine. Patients who lacked a pain medicine consult, underwent a spinal fusion procedure (those patients were part of a previously reported investigational study 11 ), had incomplete record of pain scores and/or opioid intake, or received ketamine only for the purpose of sedation were excluded. Data collected included sex, age, race, ketamine infusion duration, pain duration (acute vs chronic), pain diagnoses (vaso-occlusive episodes [VOE] , visceral, CRPS, headache, or other [mucositis, diabetic neuropathy, neurofibromatosis, and postural orthostatic tachycardia syndrome]), primary clinical diagnosis (accidental trauma, surgical trauma, and postoperative pain [patients who had a planned surgical procedure during hospitalization], functional gastrointestinal disorder [chronic and/or recurrent gastrointestinal symptoms with no identified etiology], inflammatory disease [pancreatitis or Crohn's disease], sickle cell disease, malignancy, or other), and primary pain location. Patients with pain in more than two locations were classified as having generalized pain. From the medical charts, we retrieved documentation of hemodynamic changes that warranted treatment with vasoactive agents, as well as reports of psychotropic effects, nausea, vomiting, and changes in sleep pattern. All pain scores recorded throughout admission days were collected. We then calculated average daily pain scores before (day prior to ketamine administration) and after (24 h, 48 h, and on the day after discontinuation) ketamine infusion. Pain scores were measured using the Numeric Rating Scale (NRS), the Wong-Baker FACES ® , or the Face, Legs, Activity, Cry, and Consolability (FLACC), as appropriate. At the times indicated earlier, we also collected total daily opioid intake and then calculated the daily 
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Ketamine for pain management oral morphine-equivalent (per body weight in kilograms) intake using the opioid conversion tool available at www. globalrph.com/narcoticonv.htm. 22 
Outcomes
The primary outcome was change in average pain scores from baseline to postketamine infusion. Secondary outcomes included changes in oral morphine-equivalent intake from baseline measurements to postketamine infusion and proportion of ketamine infusions that resulted in clinically meaningful reductions in pain scores and opioid intake. We defined clinically meaningful change in pain scores or opioid intake as a ≥20% reduction in pain scores and in morphine-equivalent intake from baseline to the day after ketamine discontinuation (day after ketamine -baseline/ baseline ¥100). Such a decline in pain score (20%) is larger than the 12.5% decrease in pain score suggested by others as being minimally clinically significant for adolescents with chronic pain. 23 
Ketamine administration
At our institution, ketamine prescribed by the Pain Medicine Division can be administered on regular inpatient care units where oxygen delivery set-up, suction, and resuscitation equipment are available. Trained nurses administer ketamine infusions using a locked infusion pump and patients are maintained on a cardiorespiratory monitor (heart and respiratory rate, blood pressure, and pulse oximeter). Criteria to receive subanesthetic doses of ketamine infusions include inadequate analgesia with standard pain therapy, opioid tolerance associated with undesirable side effects, opioid-induced hyperalgesia, neuropathic pain, postoperative pain in patients in whom opioid use was undesirable, or an opioid-sparing effect was needed for clinical reasons. Ketamine infusions used for end-of-life care were excluded. Exclusion criteria for ketamine administration include history of psychosis, intracranial hypertension, severe labile hypertension, or poorly controlled cardiac arrhythmia, hypersensitivity to ketamine, and age <3 months.
In our institution, ketamine infusions order sets are available, and the suggested starting doses are as follows: 1) for opioid naive patients, ketamine is started at 0.05-0.4 mg/ kg/h; 2) for opioid tolerant patients (as documented by the pain service), 0.05-1 mg/kg/h; and 3) for patients with documented opioid-induced hyperalgesia, 1 mg/kg/h. During infusions, ketamine doses could be titrated according to its indication and pain scores up to 1 mg/kg/h as allowed by the Board of Nursing.
Statistical analysis
The distributions of raw pain scores, daily opioid intake, and changes over time were tested for normality. Because the data were skewed, the Wilcoxon signed-rank test was used to test for statistical significance of within-individuals changes between baseline and posttreatment outcome measurements.
Box plots were used to examine how the individuallevel changes (between baseline and the day after ketamine discontinuation) in raw pain scores and daily opioid intake were distributed across the subgroups of the eight patient characteristics (age, sex, race, duration of pain, clinical diagnosis, type of pain, location of pain, and duration of ketamine infusion), and the distributions were tested for normality. Because the data were skewed for certain characteristics, nonparametric tests were used for all statistical analyses.
The Kruskal-Wallis test was used to compare the distribution of values across the subgroups of each patient characteristic separately. When an overall difference was detected, Dunn's test (with a Bonferroni adjustment for multiple comparisons) was then used to compare all possible pairs of subgroups and identify any statistically significant detectable differences.
The proportion of patients (95% confidence interval [CI]) who achieved clinically meaningful reductions in pain and daily opioid intake were graphed in order to visually compare how the proportions varied across the subgroups of all eight patient characteristics.
Fisher's exact test was used to examine whether the proportions varied across the subgroups of sex, race, duration of pain, clinical diagnosis, type of pain, or location of pain. A nonparametric test for trend was used to examine whether the proportion of patients with a clinically meaningful reduction in pain scores and opioid intake systematically declined across ordered age groups or by the duration of ketamine infusion. Stata 14.1/IC (StataCorp LLC, College Station, TX, USA) was used to conduct all analyses. p-values <0.05 were considered statistically significant except when Bonferroni's correction for multiple comparisons was applied. In those instances, the statistically significant p-value was calculated as 0.05/the total number of comparisons.
Results
Study cohort
We reviewed 1542 records, containing orders for subanesthetic ketamine administration (Figure 1 ). Records containing ketamine orders not written by the Pain Medicine Division were incomplete or were from patients who had undergone were excluded. Two hundred and fifty-one patients and 441 infusions, which occurred between January 2006 and April 2014, met the study eligibility criteria. Of the 441 remaining records, 57 were excluded as pain scores, and/or opioid intake data were missing during the first or second day of ketamine administration or for the 24 h after discontinuation of ketamine. Records from 24 ketamine infusions were eliminated because they consisted of a second ketamine infusion during a single hospital admission. The final study cohort included data from 230 different patients who, during 360 separate hospital admissions, received subanesthetic ketamine infusions for pain therapy. Of those, 180 patients were admitted once, while the other 50 were each admitted between two and ten times. For the purpose of this study, each admission was considered an independent event.
Patients
Patient characteristics at the time of first ketamine infusion are listed in Table 1 . The median age was 14 years (interquartile range: 10-17 years). Over the 360 ketamine infusions, most patients were from 12 to 18 years of age (58%), 6 to 11 years (17%), 19 to 21 years (14%), 3 to 5 years (5%), >22 years (4%), and 1.1 to 2.9 years (3%). Most ketamine infusions lasted 3 days (26%).
Seventy-eight percent of infusions (280) were administered to patients with acute pain and 22% to patients with chronic pain. Additionally, most ketamine infusions (50%) were administered to patients with sickle cell disease who had been admitted for VOE, whereas 17% who had postoperative pain after surgical trauma and 13% had malignancy-associated pain (Table 2) . Pain locations are listed in Table 3 . Most patients had generalized pain (25%), followed by abdominal (22%), lower extremity (21%), and chest (15%) pain.
Primary outcome
We collected average pain scores on the day prior to initiation of ketamine and on the first day of ketamine infusion. In the hospital admissions (n=331 of 441) where both values were originally available in the electronic medical record, the average pain score on the day prior to ketamine initiation (6.85 [95% CI: 6.58-7.11]) and on the first day of ketamine infusion were similar (6.84 [95% CI: 6.59-7.08]), p=0.499. Given that in all infusions, the average pain score values were available on the first day of infusion, we considered that as the baseline pain score for the final study cohort of 360 hospital admissions.
Overall, ketamine infusions were associated with significant reductions in average pain scores from the first day of The effect of ketamine infusions on raw pain scores (within-individual change) was similar comparing all age groups (p=0.842), males and females (p=0.065), all races (p=0.721), acute and chronic pain (p=0.460), and pain types (p=0.894), data not shown. In contrast, the effect of ketamine infusions on pain scores varied according to clinical diagnosis (p=0.01), infusion duration (p=0.004), and pain location (p=0.004, Figure 2) . Specifically, greater median reductions in pain scores were observed in patients with malignancy-associated pain and patients with inflammatory disease (pancreatitis and Crohn's disease), whereas the lowest were in patients with functional gastrointestinal disorder and other (cystic fibrosis, diabetes mellitus, neurofribromatosis 1, postural orthostatic tachycardia syndrome, and two cases simply coded as other, p=0.011 for overall difference, Figure 2A ). Regarding infusion durations, longer ketamine infusions yielded greater median reductions in pain scores (p=0.004, Figure 2B) 
Secondary outcomes
Regarding opioid intake, ketamine infusions were associated with significant decreases in overall average oral morphineequivalent intake from the first day of infusion (2.74 mg/kg/d [2.47-3.00], mean [95% CI]) to the day after discontinuation of ketamine (2.06 mg/kg/d [1.81-2.31]), p<0.001. There was no impact of age, sex, race, pain duration (acute vs chronic), or pain location or type on the effect of ketamine on oral morphine-equivalent intake (all p≥0.322). However, the ketamine effect on opioid intake varied according to clinical diagnosis (p=0.030, Figure 2C ) and duration of infusion (p=0.022, Figure 2D ). Specifically, greater median reductions in opioid intake were observed in patients with malignancy-associated pain and patients with sickle cell disease, whereas lesser reductions were observed in patients with accidental trauma and postoperative pain after surgical trauma (p=0.030 for overall difference, Figure 2C ). Regarding ketamine infusion duration, similar to the observation of reduction in pain scores, longer ketamine infusions yielded greater reductions in oral morphine-equivalent intake (p=0.022, Figure 2D ).
During ketamine administration, there were no records of hallucinations, changes in sleep pattern, or hemodynamic changes or arrhythmias requiring therapy in any patient.
Clinically meaningful reduction in pain score and morphine-equivalent intake
We then examined the proportion of ketamine infusions that yielded clinically meaningful changes in pain scores and opioid intake, here defined as a ≥20% reduction in pain scores and a ≥20% reduction in morphine-equivalent intake after discontinuation of the infusion compared to baseline levels, respectively. Overall, there was a ≥20% reduction in pain scores in 58% of all ketamine infusions. The proportion of infusions that yielded a 20% or greater reduction in pain scores varied according to clinical diagnosis (p=0.003), pain location (p=0.012), age (p=0.039), and duration of infusion (p=0.017, Figure 3 ). For example, the highest proportion of infusions associated with clinically meaningful reduction in pain scores were observed among infusions administered to cancer patients and patients with inflammatory diseases and the lowest among patients with functional gastrointestinal disorders ( Figure 3A ). There was a trend for higher frequency of meaningful reduction in pains scores in males (63%) than in females (54%), p=0.056. Conversely, the frequency of Regarding the frequency of a meaningful reduction in opioid intake, in 52% of ketamine infusions there were 20% or greater reductions in opioid intake. The frequency of infusions associated with ≥20% reduction in opioid intake varied according to duration of ketamine infusion (p=0.030), with longer durations infusions being more likely to result in a meaningful reduction in opioid intake (data not shown). Conversely, the frequency of a meaningful reduction in opioid intake did not vary with the clinical diagnosis, type of pain, duration of pain, location of pain, age, sex, or race.
Discussion
In this cohort study involving a large number of children, adolescents, and young adults, we examined the effects of subanesthetic ketamine infusions on pain intensity and opioid intake. We found that continuous subanesthetic ketamine infusions administered to children, adolescents, and young adults with inadequate pain control in a regular inpatient care unit setting were safe and not associated with significant psychotropic effects or hemodynamic side effects that warranted treatment. We do acknowledge that increases in blood pressure could occur during administration of ketamine; however, we recorded only instances where changes in blood pressure warranted treatment with vasoactive drugs. Further, while there were no records of hallucinations, it is possible that the presence of hallucinations in young children could have manifested as dysphoria and those were not recorded. Nevertheless, ketamine was associated with significant decreases both in pain scores and opioid intake and these effects varied according to clinical diagnosis, infusion duration, and pain location.
The greatest reductions in pain scores were observed in patients with cancer pain and patients with inflammatory processes including pancreatitis and Crohn's disease, whereas patients with functional gastrointestinal disorder, diabetes mellitus, neurofibromatosis 1, and postural orthostatic 
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Ketamine for pain management tachycardia syndrome had less reduction in pain scores. We also found that ketamine infusions in patients with cancer pain, inflammatory diseases, and postoperative pain were associated with a greater (over 75% of infusions) frequency of meaningful reduction in pain scores (here defined as a ≥20% reduction). Therefore, this study is informative in that its findings can be used to help design much-needed randomized trials to evaluate the effect of ketamine in the treatment of pain in children, adolescents, and young adults with poorly controlled pain.
Over the past few years, the use of ketamine for the treatment of cancer pain has been the focus of significant debate. 15, 24, 25 The discussion ensued after publication of a randomized placebo-controlled clinical trial enrolling 185 adult participants with cancer pain, who received ketamine or placebo delivered subcutaneously. 26 That trial showed that ketamine, administered over 5 days in a dose-escalating regimen, had no clinical benefit compared to placebo and was associated with increased adverse events. 26 However, researchers argue that the trial used a subcutaneous regimen not commonly utilized, the ketamine doses were escalated rapidly, and the study population was very heterogeneous, all of which are potential limitations of that trial. 25 Therefore, researchers argue that those issues should tailor the interpretation of the findings 26 and those negative results should not discard the potential role of ketamine in patients with cancer pain. 25 After publication of those negative results, a survey of clinicians demonstrated that the practice of using ketamine was continued by 30% of the respondents 24 and the use of ketamine to treat cancer pain and other types of pain by many specialists has continued. 19, 24 On balance, one must recognize that the existing data on the use of ketamine in children with cancer pain are very limited, most reports consist of small case series, and randomized clinical trials of ketamine to treat cancer pain in children are lacking. Nevertheless, we have sided with those who argue that, while clinical trials are needed, the practice of using ketamine in children with cancer pain might be one to be adopted when other options are unavailable. Concerning acute postoperative pain, we found in the present study that the opioid-sparing effect of ketamine was minimal. This finding is consistent with our results from a previous randomized placebo-controlled trial, where ketamine administered in the intraoperative and postoperative periods did not yield an opioid-sparing effect in adolescents with scoliosis undergoing spinal fusion. 11 Interestingly, a more recent trial and a new meta-analysis 12 also showed lack of beneficial effect of ketamine in postoperative pain. 27 It is important to note that one limitation of the most recent study in adolescents undergoing spinal fusion 27 as well as ours 11 is that neither study examined the effect of ketamine on chronic postsurgery pain. Nevertheless, our findings from the present study are discrepant to those showing that low-dose ketamine infusion during the perioperative period yields opioid-sparing effects in adults undergoing major surgeries. 28 While we acknowledge that, in adults, there are data to support the use of ketamine in the perioperative period, in our institution, we no longer routinely use ketamine to treat postoperative pain in our pediatric patients.
One must acknowledge the limitations of this study, which call for caution in interpreting its results. First, we report on the use of ketamine in a heterogeneous population of children, adolescents, and young adults and lack a control group. Further, while there was consistency regarding the ketamine administration regimen and indications for its use, timing of administration, and titration of opioids and ketamine doses were left to the discretion of the pain medicine attending. Additionally, for the purpose of this study, we regarded ketamine infusions administered to the same patients as independent infusions and we did not account for the potential confounding effect of repeated measures by repeatedly administering ketamine to some patients.
Conclusion
In conclusion, despite its limitations, this study suggests that in an inpatient setting, the treatment of pain in children, adolescents, and young adults with subanesthetic doses of ketamine is feasible and safe in regular patient care units. The study is also informative in that it suggests that ketamine might have a differential beneficial effect in patients with certain pain syndromes. Additionally, this study raises a number of hypotheses to be tested in future clinical trials to more definitively determine which patients would benefit from this therapeutic modality. Finally, our findings can be used to determine sample and effect sizes for future randomized trials to evaluate the role of ketamine for the treatment of pain in children, adolescents, and young adults.
